Cyclosporin A treatment for membranoproliferative glomerulonephritis type II.
A nephrotic patient with membranoproliferative glomerulonephritis type II (MPGN II) was treated with cyclosporin A (CSA) and alternate-day low-dose prednisolone. This patient developed the nephrotic syndrome twice. The second episode of the nephrotic syndrome was steroid resistant, and therefore this patient was treated with a CSA regimen. During treatments with alternate-day low-dose prednisolone and CSA, this patient recovered from the nephrotic syndrome. We conclude that CSA therapy may be effective for patients with the steroid-resistant nephrotic syndrome caused by MPGN II.
Kiyomasu
Takahiro
T
Department of Pediatrics, Kyoto National Hospital, 1-1 Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan. tkiyomas@kyotolan.hosp.go.jp
Shibata
Minoru
M
Kurosu
Hideo
H
Shiraishi
Kazuhiro
K
Hashimoto
Hisako
H
Hayashidera
Tadashi
T
Akiyama
Yuichi
Y
Takeda
Nobuaki
N
D002648:Child; D003176:Complement C3 / Q000378:metabolism; D016572:Cyclosporine / Q000627:therapeutic use*; D005920:Glomerular Mesangium / Q000166:cytology / Q000473:pathology; D015432:Glomerulonephritis, Membranoproliferative / Q000188:drug therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use
D003176:Complement C3; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone